The Claritas Rx data model offers valuable insights for Servier teams.

The primary distinction of Claritas Rx lies in its method of data integration. “Our greatest strength is uniting diverse data sources and linking them to deliver actionable insights for field and pharmacy teams that directly influence a patient’s access to therapy,” Athena explains.

This adaptability goes beyond data integration to encompass how information is displayed. “We can achieve this for customers with a single drug on the market, as well as for those with multiple brands, where we examine brand and disease-specific insights,” she notes.

A crucial aspect focuses on longitudinal data that tracks patients over time. “Thanks to the wide range of data sources we integrate, our specialty is in providing enriched longitudinal patient-level data.”

The Servier partnership is progressing towards predictive healthcare modeling.

The collaboration with Servier is now transitioning to a phase that emphasizes more advanced analytical methods. As Athena describes, future developments will aim to foresee access challenges before they arise.

“We’re enhancing our analytics and utilizing predictive capabilities to provide teams with insights into where patients may encounter difficulties with therapy access before it occurs,” she states.

This shift towards predictive capabilities aligns with broader trends in healthcare. As treatments become increasingly personalized, Claritas Rx seeks to ensure that support systems are equally customized to individual patient needs.

“We’re in an era of personalized medicine and tailored healthcare options. Access to therapy is also personalized,” Athena remarks. “Our next goal is to become more prescriptive: not just offering standardized insights for the entire population, but providing manufacturers and pharmacies with insights into the specific needs of individual patients regarding their access to therapy.”